Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1990 Oct;81(10):994–1002. doi: 10.1111/j.1349-7006.1990.tb03337.x

Inactivation of Human Tumor Cell Pro‐urokinase by Granulocyte Elastase

Naohiro Kanayama 1, Toshihiko Terao 1
PMCID: PMC5917968  PMID: 2121685

Abstract

Supernatant obtained from granulocytes stimulated in the presence of cytochalasin B by the chemotactic peptide N‐formyl‐norleucyl‐leucyl‐phenylalanyl‐norleucyl‐tyrosyl‐lysine displayed an inhibitory effect on the plasmin‐dependent conversion of tumor urokinase‐type plasminogen activator proenzyme (pro‐uPA) to the active form of uPA. Moreover, the supernatant was also found to inhibit the fibrinolytic activity of human vulva (A431) and breast (MCF7) carcinoma cell lines, which contain large amounts of pro‐uPA, by 87% and 96%, respectively. By using eglin C (elastase inhibitor) and a monoclonal antibody to elastase (proteolytic activity blocker of the enzyme), elastase was identified as the key enzyme of the supernatant in these phenomena. Purified elastase converted pro‐uPA to an enzymatically inactive molecule composed of two polypeptide chains of Mr = 33,000 and 22,000 linked to each other by a disulfide bond. Elastase‐containing granulocytes were identified by immunohisto‐chemistry techniques in the tissues of squamous cell carcinoma and adenocarcinoma of uterus. The cells were found close to the tumor cells and in the stroma surrounding the tumor nests. By immunohistochemical staining, uPA was also found in the tumor cells. Evidently, elastase released by chemotactically activated granulocytes, which are attracted into tumor tissues, may inhibit the conversion of pro‐uPA to enzymatically active uPA in the tumor cells.

Keywords: Granulocyte elastase, Pro‐urokinase, Fibrinolysis, Breast cancer, Uterine cancer

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

References

  • 1.Cajot, J. F., Kruithof, E. K. O., Schleuning, W. D., Sordat, B. and Bachamann, F.Plasminogen activators, plasminogen activator inhibitors and procoagulant analysed in twenty human tumor cell lines. Int. J. Cancer, 38, 719–727 (1986). [DOI] [PubMed] [Google Scholar]
  • 2.Corti, A., Nolli, M. L., Soffientini, A. and Cassani, G.Purification and characterization of single‐chain urokinase type plasminogen activator (pro‐urokinase) from human A431 cells. Thromb. Haemostasis. 56, 219–224 (1986). [PubMed] [Google Scholar]
  • 3.Stump, D. C., Lijnen, H. R. and Collen, D.Purification and characterization of single‐chain urokinase‐type plasminogen activator from human‐cell culture J. Biol. Chem., 261, 1274–1278 (1986). [PubMed] [Google Scholar]
  • 4.Markus, G.The relevance of plasminogen activators to neoplastic growth. Enzyme, 40, 158–172 (1988). [DOI] [PubMed] [Google Scholar]
  • 5.Gurewich, V., Pannel, R., Louie, S., Kelley, P., Suddith, A. L. and Grennlee, R.Effective and fibrin‐specific clot‐lysis by a zymogen precursor form of urokinase (pro‐urokinase) J. Clin. Invest., 73, 1731–1739 (1984). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dvorak, H. F.Tumors: wounds that do not heal. N. Engl. J. Med., 315, 1650–1659 (1986). [DOI] [PubMed] [Google Scholar]
  • 7.Wilhelm, O., Hafter, R., Coppenrath, E., Pflanz, M., Schmitt, M., Babic, R., Linke, R., Gossner, W. and Graeff, H.Fibrin‐fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res., 48, 3507–3514 (1988). [PubMed] [Google Scholar]
  • 8.Kruithof, E. K. O., Tran‐Thang, C., Ransijin, A. and Bachmann, F.Demonstration of a fast‐acting inhibitor of plasminogen activators in human plasma. Blood, 64, 907–913 (1984). [PubMed] [Google Scholar]
  • 9.Kruithof, E. K. O., Vassalli, J. D., Schleunig, W. D., Mattaliano, R. J. and Bachmann, F.Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U‐937. J. Biol. Chem., 261, 11207–11213 (1986). [PubMed] [Google Scholar]
  • 10.Kanayama, N., Horiuchi, K. and Terao, T.The role of human neutrophil elastase in premature rupture of membranes. Asia Oceania J. Obstet. Gynecol., 14, 389–397 (1988). [DOI] [PubMed] [Google Scholar]
  • 11.Laemmli, U. K.Cleavage of structural proteins during assembly of the head of bacteriophage. Nature, 27, 680–685 (1970). [DOI] [PubMed] [Google Scholar]
  • 12.Kruithof, E. K. O., Ransijin, A. and Bachmann, F.Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators. Thromb. Res., 28, 251–260 (1982). [DOI] [PubMed] [Google Scholar]
  • 13.Borregaard, N., Heiple, J. M., Simons, E. R. and Clark, R. A.Subcellular localization of the b‐cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J. Cell Biol., 97, 52–59 (1983). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Moroz, L. A.Mini‐plasminogen: a mechanism for leukocyte modulation of plasminogen activation urokinase. Blood. 58, 97–104 (1981). [PubMed] [Google Scholar]
  • 15.Weiz, J. L., Landman, S. L., Crowly, K. A., Birken, S. and Morgan, F. J.Development of an assay for in vitro human neutrophil elastase activity. J. Clin. Invest., 78, 155–162 (1986). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wojtecka‐Lukasik, E., Kaczanowska, J., Tomczak, Z., Sopata, I. and Kopec, M.Efeect of neutral proteases from human leukocytes on plasma fibronectin. Thromb. Res., 33, 471–476 (1984). [DOI] [PubMed] [Google Scholar]
  • 17.Heiple, J. M. and Ossowski, L.Human neutrophil activator is localized in specific granules and is translocated to the cell surface by exocytosis. J. Exp. Med., 164, 826–840 (1986). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Goldleski, J. J., Lee, R. E. and Leighton, J.Studies on the role of polymorphonuclear leukocytes in neoplastic disease with the chick embryo and Walker carcinoma 256 in vivo and in vitro Cancer Res., 30, 1986–1993 (1970). [PubMed] [Google Scholar]
  • 19.De Bruin, P. A. F., Griffioen, G., Verspaget, H. W., Verheijen, J. H., Dooijewaard, G., Inhg, H. F. and Lamers, C. B. W.Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res., 48, 4520–4524 (1988). [PubMed] [Google Scholar]
  • 20.Markus, G., Takita, H., Camiol, S. M., Corsanti, J. G., Evers, J. L. and Hobika, H.Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res., 40, 841–848 (1980). [PubMed] [Google Scholar]
  • 21.Kirchheimer, J. C., Koller, A. and Binder, B. R.Isolation and characterization of plasminogen activators from hyperplastic and melignant prostate tissue. Biochim. Biophys. Acta, 797, 256–265 (1984). [DOI] [PubMed] [Google Scholar]
  • 22.Evers, J. L., Patel, J., Madeja, J. M., Scelastaseider, S. L., Hobika, G. H.Camiolo, S. M. and Markus, G.Plasminogen activator activity and composition in human breast cancer. Cancer Res., 42, 219–226 (1982). [PubMed] [Google Scholar]
  • 23.Dano, K., Andreasen, P. A., Grondahl‐Hansen, J., Kristensen, P., Nielsen, L. S. and Skriver, L.Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139–266 (1985). [DOI] [PubMed] [Google Scholar]
  • 24.Lsyer, G. T., Cederholm‐Williams, S. A., Gaffney, P. J., Houflbrook, S., Mahmound, M., Pattison, M. and Burnard, K. G.Urokinase — the enzyme responsible for invasion and metastasis in human breast carcinoma? Fibrinolysis, 1, 237–240 (1987). [Google Scholar]
  • 25.Schmeller, M. L., Hafter, R., Stemberger, A. and Graeff, H.Plasmin and elastase induced fibrin degradation products and their action on vascular permeability: an experimental study In“Fibrinogen,” ed. Henschen A., Graeff H. and Lottspeich F., pp. 361–364 (1982). Walter de Gruyter, Berlin, New York. [Google Scholar]
  • 26.Boyle, M. D. P., Chdiodo, V. A., Lawman, J. P., Gee, A. R. and Young, M.Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo J. Immunol., 139, 169–174 (1987). [PubMed] [Google Scholar]
  • 27.Gudewicz, P. W. and Gilboa, N.Human urokonase‐type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun., 147, 1175–1181 (1987). [DOI] [PubMed] [Google Scholar]
  • 28.Gerrad, T. L., Cohen, D. J. and Kaplan, A. M.Human neutrophil‐mediated cytotoxicity to tumor cells J. Natl. Cancer Inst., 66, 483–488 (1981). [PubMed] [Google Scholar]
  • 29.Clark, R. A. and Klebanoff, S. J.Neutrophil‐mediated tumor cell cytotoxicity: role of the peroxidase system. J. Exp. Med., 141, 1442–1447 (1975). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Weiss, S. J., Peppin, G., Oritz, X., Ragsdale, C. and Test, S. T.Oxidative autoactivation of latent collagenase by human neutrophils. Science, 227, 747–749 (1985). [DOI] [PubMed] [Google Scholar]
  • 31.Dvorak, A. M., Connell, A. B., Proppe, K. and Dvorak, H. F.Immunologic rejection of mammary adenocarcinoma (TA3‐St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation. J. Immunol., 120, 1240–1248 (1978). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES